Osteolytic cancers (breast, lung and RCC) secrete growth factors and cytokines (including PTHrP) which act on osteoblasts to increase their expression and secretion of RANKL, whilst decreasing their secretion of the RANKL decoy receptor OPG. This evidence concerns the gene TNFSF11 and cancer.